# POM — Pomdoctor Ltd ADR · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** POM  
**Sources:** 19  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-pom-pomdoctor-ltd-adr-catalysts-narrative-risks-10129

---

# POMDOCTOR LIMITED (Nasdaq: POM) — Research Note as of 2026-10-30

PomDoctor Limited is a Guangzhou, China–based foreign private issuer operating an online pharmaceutical retail portal and a chronic-disease internet-hospital platform in China, with a stated strategic pivot toward AI-enabled "predictive healthcare" [[1]](https://www.morningstar.com/news/pr-newswire/20261009cn67655/pomdoctor-limited-announces-receipt-of-nasdaq-staff-delisting-determination), [[2]](https://finance.yahoo.com/healthcare/articles/pomdoctor-limited-announces-termination-adr-123000796.html), [[17]](https://stockanalysis.com/stocks/pom/), [[20]](https://www.stocktitan.net/overview/POM/). Historically it listed via an unsponsored ADR structure (ADS ticker POM); as noted below, it is in the process of ending that structure. All figures below are point-in-time snapshots from third-party providers and conflict materially across sources — see the "data reliability" note.

## Key Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-pom-pomdoctor-ltd-adr-catalysts-narrative-risks-10129 (free to sign up)._